Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-β and gal-1/NRP-1/VEGFR2 pathways-Reference-Cited by-同舟云学术

Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-β and gal-1/NRP-1/VEGFR2 pathways

Published:2023-11 Issue: Volume:959 Page:176066
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Noah Ashraf A.,El-Mezayen Nesrine S.^ORCID,El-Ganainy Samar O.^ORCID,Darwish Inas E.,Afify Elham A.

Funder

Alexandria Faculty of Medicine, Alexandria University

Publisher

Elsevier BV

Subject

Pharmacology

Reference77 articles.

1. Empagliflozin, SGLT 2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of Klotho expression;Abbas;N. Schmied. Arch. Pharmacol.,2018

2. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application;Abdelhamid;Biomed. Pharmacother.,2022

3. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus;Abdul-Ghani;Am. J. Physiol. Ren. Physiol.,2015

4. Modeling of hypo/hyperglycemia and their impact on breast cancer progression related molecules;Adham;PLoS One,2014

5. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats;Aragon-Herrera;Biochem. Pharmacol.,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats;Cells;2024-03-19

2. Efficacy of SGLT2 inhibitors in IgA nephropathy associated with alcoholic liver cirrhosis accompanied by nephrotic syndrome: a case report;Frontiers in Nephrology;2024-01-22